V. Evaluation of Cross-Immunity against Type 1 Dengue Fever in Human Subjects Convalescent from Subclinical Natural Japanese Encephalitis Virus Infection and Vaccinated with 17D Strain Yellow Fever Vaccine
Fourteen patients infected with schistosomiasis mansoni were treated with urea stibamine (Squibb). The drug was administered intravenously; the total amount given varied from 3.40 to 10.125 g.
Twelve out of 14 patients had stools negative for ova of S. mansoni when examined on the 30th day after the end of treatment and have remained negative thereafter for an additional period of 90 days.
One patient with the stools positive 60 days after treatment, had received the smallest amount of drug. The presence of ova in the stools of this patient may be attributed to the insufficient amount of drug administered.
Another patient died during hospitalization as a result of treatment. Toxic reactions to the drug occurred frequently among all patients and consisted of flushing of face, facial edema, hoarseness, dyspnea, tachycardia, abdominal pain, nausea, vomiting, congestion of conjunctival vessels, headache, weakness, loss of appetite, fever, decrease in white cell count, and albuminuria.
Although the patients have had stools negative for ova of S. mansoni during a period of 4 months following treatment, the true efficacy of the drug can be evaluated only by the results of examinations done through longer periods of time. If further observations prove that the disappearance of ova from stools during treatment with this drug is due to the actual death of the worms, one would then feel justified in recommending its use under careful medical supervision.